Venous Leg Ulcer Clinical Trial
Official title:
Effect of Polidocanol Endovenous Microfoam (PEM) Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in Venous Leg Ulcers (VLUs)
Verified date | September 2017 |
Source | OhioHealth |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the addition of polidocanol endovenous microfoam (PEM) to compression
therapy to determine effectiveness in improving the healing of venous leg ulcers (VLUs) in
adults with severe venous disease of the great saphenous vein (GSV). All participants will
receive treatment with Varithena and compression therapy.
The purpose of this study is to assess whether the use of PEM to correct superficial axial
and varicose vein reflux is effective in improving healing of VLUs, over treatment with
compression alone.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | September 12, 2017 |
Est. primary completion date | September 12, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age = 18 years old - Active VLU with a CEAP classification of C6 - Non-healing VLU = 1 month but not greater than 24 months - In the case of more than one ulcer, the largest ulcer (compliant with study criteria) will be chosen as the study ulcer and treated in the study. Other ulcerations, if present on the same leg must be at least 2cm apart from the study ulcer. - Demonstrable GSV insufficiency (as per the Society for Vascular Surgery [SVS] and the American Venous Forum [AVF] Guidelines) via venous insufficiency study (VIS) (11) - VLU considered non-healing (clinically defined as =70% wound improvement) after a 4-5 week run-in period with compression therapy - Venous leg ulcer size = 2cm2 within the great saphenous distribution and must be visualized in one plane to allow for image collection of the entire wound in one photo by the Silhouette device. - The ulcer must extend through both the epidermis and dermis, with no exposed tendon or bone - The ulcer must be located below the knee - The ulcer bed must have some viable tissues with some granulation tissue - Able to tolerate effective compression bandaging - Patients able to walk independently with or without mobility aids - Ability to comprehend and sign an informed consent document and complete study questionnaires in English - Able and willing to attend all follow up visits Exclusion Criteria: - Age < 18 years old - Small saphenous vein (SSV) distribution VLUs - Patients who had previously received interventions for underlying venous disease or prior VLU treatments that would not be considered to be conservative, in the opinion of the principal investigator - Exposed bone, tendon, or fascia - Deep vein reflux unless clinically insignificant in comparison to superficial reflux - Patients with leg ulceration etiology other than venous insufficiency - Severe rheumatoid arthritis - History of radiotherapy to the ulcer site - Uncontrolled congestive heart failure (left or right sided heart failure) - Receiving corticosteroids or immune suppressive therapy - Active clinical infection of the ulcer site, however, patients may be entered into the study after successful treatment of infection - History of collagen vascular disease - History of known malnutrition (albumin <3.0 g/dL) - History of known uncontrolled diabetes [hemoglobin A1c (HgbA1c) >8.0%] - History of known arterial insufficiency [ankle-brachial index (ABI) <0.7, transcutaneous oxygen (tcpO2) <35 mmHg, or toe-brachial index (TBI) <0.4] - Signs of cellulitis, osteomyelitis, or necrotic or avascular ulcer bed(s) - Active sickle cell disease - Patients diagnosed with DVT or phlebitis in the affected limb in the last 6 months, or with acute pulmonary embolism (PE) in the last 6 months (contraindication to PEM) - Known allergic response to polidocanol or heparin, including history of heparin-induced thrombocytopenia, and/or multiple allergic reactions (contraindication to PEM) - Chronic renal disease, if deemed by the principal investigator to be severe enough to interfere with wound healing - Known active or recurrent cancer, or currently receiving chemotherapy or radiation therapy - Poorly controlled asthma - Pulmonary edema - Major surgery, prolonged hospitalization, or pregnancy within 3 months of screening - Minor surgery within 1 month of screening - Current alcohol or drug (illicit or prescription) abuse - Pregnant or lactating women - History of stroke - Unable to comply with the procedures described in the protocol - Unable to comply with compression therapy recommendations - Unable to give informed consent - Non-English speaking - Enrolled in a clinical evaluation for another investigational wound-care device or drug |
Country | Name | City | State |
---|---|---|---|
United States | OhioHealth Riverside Methodist Hospital | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
OhioHealth | BTG International Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ulcer healing rate | We will determine the change in ulcer healing rate following PEM treatment. Ulcer healing rate will be measured as the relative weekly change in ulcer perimeter (cm) from baseline, until either until fully healed, or up to the final active study visit at 12 weeks (whichever is sooner). Pre-treatment healing rate will be measured as the relative change in ulcer perimeter (cm) from baseline per week over the 4-5 week run-in period. | 12 weeks | |
Secondary | Proportion of patients who successfully heal | We will determine the proportion of patients who successfully heal by 12 weeks. "Successful" healing will be defined as complete resolution of the ulcer (0 cm), with a lack of disruption of the epithelium at the ulcer site. | 12 weeks | |
Secondary | Proportion of patients who experience symptomatic pulmonary embolism and deep vein thrombosis (PE and DVT, respectively) and other drug-related adverse events (AEs) | We will determine the proportion of patients who experience symptomatic pulmonary embolism and deep vein thrombosis (PE and DVT, respectively) and other drug-related adverse events (AEs) at 12 weeks (or the last active study visit if healed prior to 12 weeks). The most commonly reported drug-related AEs (occurring in =3% of patients) include pain/discomfort in extremity, infusion site thrombosis (retained coagulum), injection site hematoma or pain, and superficial thrombophlebitis. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03903692 -
A Comparative Evaluation of a MPS Dressing and a CMC Dressing on Subjects With Lower Extremity Venous Ulcers
|
N/A | |
Completed |
NCT03257254 -
Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
|
||
Recruiting |
NCT03666754 -
Early Glue Saphenous Vein Ablation With Compression Versus Compression Alone in the Healing of the Venous Ulcer
|
N/A | |
Withdrawn |
NCT02912858 -
Intermittent Pneumatic Compression of the Foot vs Geko Plus R-2 Neuromuscular Electrostimulation Device in Venous Leg Ulcer Patients
|
N/A | |
Completed |
NCT02482038 -
Geko Venous Leg Ulcer Study
|
N/A | |
Completed |
NCT02652572 -
Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers
|
Phase 1 | |
Unknown status |
NCT01658618 -
Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer
|
N/A | |
Completed |
NCT05646121 -
Suprasorb® A + Ag in the Treatment of Wounds at Risk of Infection and Infected Wounds
|
||
Completed |
NCT03077165 -
Dose-response Relationship Study of S42909 on Leg Ulcer Healing
|
Phase 2 | |
Completed |
NCT04461132 -
The Effect of Manual Lymphatic Drainage
|
N/A | |
Completed |
NCT05974982 -
Treatment Outcome of Autologous PRP Versus Conventional Therapy Among Patients With Chronic Venous Leg Ulcers
|
Phase 1 | |
Completed |
NCT04011371 -
Cyanoacrylate Closure for Treatment of Venous Leg Ulcers
|
N/A | |
Not yet recruiting |
NCT03543007 -
Evaluating the Safety and Efficacy of GrafixPLâ„¢PRIME for the Treatment of Chronic Venous Leg Ulcers
|
N/A | |
Completed |
NCT03286140 -
Early Venous Reflux Ablation Ulcer Trial
|
N/A | |
Recruiting |
NCT05588583 -
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
|
N/A | |
Not yet recruiting |
NCT04613687 -
Efficacy and Safety of a New Compression System URGO BD001 in the Treatment of VLU (FREEDOM)
|
N/A | |
Recruiting |
NCT05549609 -
A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg Ulcers
|
Phase 1/Phase 2 | |
Recruiting |
NCT05409976 -
The GORE® VIAFORT Vascular Stent IVC Study
|
N/A | |
Not yet recruiting |
NCT05089890 -
Clinical Investigation of Sorbact® Dressings
|
N/A | |
Not yet recruiting |
NCT03670329 -
Management of Infection Risk in Non-comparative Trial (MINT)
|
N/A |